PŘEHLEDOVÉ ČLÁNKY Mikrobióm a ateroskleróza E18 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék. 2024;70(8):E15-E18 / www.casopisvnitrnilekarstvi.cz Záver Rôzne bakteriálne druhy môžu prispievať k patogenéze aterosklerózy rôznymi mechanizmami, vrátane produkcie toxínov a metabolitov, stimuláciou zápalových reakcií, či inváziou buniek hostiteľa. Cieľom budúceho pátrania je lepšie pochopiť mechanizmy, ktorými mikrobióm ovplyvňuje vývoj aterosklerózy, a identifikovať nové terapeutické ciele pre prevenciu a liečbu. PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti: Publikace byla zpracována s využitím uvedené literatury a nebyla publikována ani zaslána k recenznímu řízení do jiného média. Střet zájmů: Žádný. Financování: Ne. Poděkování: Ne. Registrace v databázích: N/A. Projednání etickou komisí: N/A. LITERATURA 1. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. 2. Rinninella E, Raoul P, Cintoni M, et al. What Is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms 2019, 7, 14. 3. Sonnenburg JL, Bä ckhed, F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535:56-64 4. Olvera-Rosales LB, Cruz-Guerrero AE, Ramírez-Moreno E, et al. Impact of the Gut Microbiota Balance on the Health-Disease Relationship: The Importance of Consuming Probiotics and Prebiotics. Foods. 2021;10(6):1261. 5. Bä ckhed F, Fraser CM, Ringel Y, et al. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe. 2012;12:611-22. 6. Jonsson A, Bäckhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol. 2017;14:79-87. 7. Liu Q, Li YC, Song X, et al. Both gut microbiota and cytokines act to atherosclerosis in ApoE-/- mice. Microb Pathog. 2019;103827. 8. Zhu Q, Gao R, Zhang Y, et al. Dysbiosis signatures of gut microbiota in coronary artery disease. Physiol Genomics. 2018. 9. Yvan-Charvet L, Welch C, Pagler TA, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation. 2008;118(18):1837-1847. 10. Chacón MR, Lozano-Bartolomé J, Portero-Otín M, et al. The gut mycobiome composition is linked to carotid atherosclerosis. Benef Microbes. 2018;9:185-98. 11. Kozarov E. Bacterial invasion of vascular cell types: vascular infectology and atherogenesis. Future. Cardiol. 2012;8(1):123-138. 12. Liu X, Xie Z, Sun M, Wang X, Li J, Cui J, et al. Plasma trimethylamine N- oxide is associated with vulnerable plaque characteristics in CAD patients as assessed by optical coherence tomography. Int J Cardiol. 2018;265:18- 23. 13. Koren O, Spor A, Felin J, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A. 2011;108 Suppl 1(Suppl 1):4592-4598. 14. Karlsson FH, Fåk F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245. 15. Choroszy M, Litwinowicz K, Bednarz R, et al. Human Gut Microbiota in Coronary Artery Disease: A Systematic Review and Meta-Analysis. Metabolites. 2022;12(12):1165. 16. Kazemian N, Mahmoudi M, Halperin F. et al. Gut Microbiota and Cardiovascular Disease: Opportunities and Challenges. Microbiome 2020, 8, 36. 17. Kriaa A, Bourgin M, Potiron, A, et al. Microbial Impact on Cholesterol and Bile Acid Metabolism: Current Status and Future Prospects. J. Lipid Res. 2019;60:323-332. 18. Wexler A.G, Goodman A.L. An Insider’s Perspective: Bacteroides as a Window into the Microbiome. Nat. Microbiol. 2017;2:17026. 19. Yoshida N, Yamashita T, Kishino S, et al. A Possible Beneficial Effect of Bacteroides on Faecal Lipopolysaccharide Activity and Cardiovascular Diseases. Sci. Rep. 2020;10:13009. 20. Yoshida N, Emoto T, Yamashita T, et al. Bacteroides Vulgatus and Bacteroides Dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation 2018;138:2486-2498. 21. Sasaki N, Takeuchi H, Kitano S, et al. Dynamic analysis of Porphyromonas gingivalis invasion into blood capillaries during the infection process in host tissues using a vascularized three-dimensional human gingival model. Biomater Sci. 2021;9(19):6574-6583. 22. Grigorieva I. Atherosclerosis and trimethylamine-N-oxide — the gut microbiota potential. Russian Journal of Cardiology. 2022. 23. Gaetti-jardim E, Marcelino SL, Feitosa AC, et al. Detection of bacteria in atheromatous plaques of patients with coronary artery disease by polymerase chain reaction. Anaerobe. 2009;15(3):89-92. 24. Hansen GM, Greve JH, Greve ML. Pseudomonas aeruginosa microcolonies in coronary thrombi. Eur J Clin Microbiol Infect Dis. 2016. 25. Tungland B. Dysbiosis of the microbiota: therapeutic strategies utilizing dietary modification, pro- and prebiotics and fecal transplant therapies in promoting normal balance and local GI functions. In: Elsevier; 2018:381-419. doi:10.1016/B978-0-12814649-1.00009-0. 26. Gao M, Heng X, Jin J, Chu W. Gypenoside XLIX ameliorate high-fat diet-induced atherosclerosis via regulating intestinal microbiota, alleviating inflammatory response and restraining oxidative stress in ApoE−/− mice. Pharmaceuticals. 2022. 27. Yan N, Wang L, Li Y, et al. Metformin intervention ameliorates AS in ApoE-/- mice through restoring gut dysbiosis and anti-inflammation. PLoS ONE. 2021.
RkJQdWJsaXNoZXIy NDA4Mjc=